Diatech Pharmacogenetics

About Diatech Pharmacogenetics

Diatech Pharmacogenetics operates as a specialized developer and producer of genomics testing solutions tailored for precision medicine in oncology. Founded in 1996 by Fabio Biondi, the company is headquartered in Jesi, Italy. Mr. Biondi, who holds a degree in pharmacy, began his career in 1977 at Sclavo S.p.A., a company focused on in-vitro diagnostic kits. His extensive experience culminated in becoming the Commercial Director in 1994, the same year he participated in the founding of Diatech. His journey reflects a deep-rooted expertise in the diagnostics field, which has been instrumental in shaping the company's direction.

The firm's business model is centered on the development, manufacturing, and sale of CE-IVD certified diagnostic kits and reagents. These products are sold to cancer centers, laboratories, and hospitals, enabling them to conduct molecular diagnostics in-house. By providing end-to-end solutions, from sample extraction to bioinformatic analysis and reporting, Diatech simplifies complex genetic testing procedures. This approach allows clinicians to analyze gene mutations from patient samples to personalize cancer treatments, aiming to enhance drug efficacy and minimize side effects. A significant portion of revenue, reportedly 20%, is reinvested into research and development, fueling its product pipeline.

Diatech offers a comprehensive portfolio of products for various molecular diagnostic techniques, including real-time PCR, mass spectrometry, and Next Generation Sequencing (NGS). A key offering is the EasyPGX® system, an automated platform that supports both RT-PCR and library preparation for NGS, designed to make molecular oncology more accessible. The company has developed kits for analyzing both solid and hematological tumors, as well as solutions for "liquid biopsies," which analyze circulating tumor DNA from a simple blood sample. This is particularly valuable for monitoring disease progression or when tumor tissue is difficult to access surgically. In April 2023, the company secured a strategic growth investment from TA Associates, a global private equity firm, to accelerate international expansion and product development, while the founder and management retained majority ownership.